BluMaiden Biosciences, a biotechnology company based in Singapore, has secured funding to advance its small molecule drug discovery efforts. Utilizing AI-guided computational genetics and chemistry, BluMaiden aims to explore the extensive chemical space within the human body to develop new medicines. This funding round was led by Elev8.vc, a deep tech venture capital firm, with participation from SEEDS Capital, the investment arm of Enterprise Singapore.
The funds will accelerate BluMaiden’s commercialization efforts in Singapore and the United States. Through its tech solutions, the company aims to enhance drug discovery processes and open new frontiers for medicine development. “We warmly welcome Elev8 and SEEDS Capital to BluMaiden”, said Dr. Damien Keogh, CEO of BluMaiden Biosciences.
“Our technology is ready to be commercialized. We have validated our value proposition with potential partners and clients in leading healthcare and life science companies in Singapore and the United States. Our Pharma Services produces actionable clinical insights that enhance clinical trial decision-making for our clients whilst providing our flagship MAIDENTM Drug Discovery division with unique access to diverse human-first evidence and clinical samples and metadata”, he added.
BluMaiden enhances drug discovery by utilizing AI-guided computational genetics and chemistry to explore the extensive chemical space within the human body. The company's human-centric approach uncovers novel structural scaffolds and motifs from rich bioactive natural products, facilitating the discovery of new molecules with significant biological relevance and clinical potential. BluMaiden's Maiden platform boosts the likelihood of identifying new therapeutics and targeting previously undruggable sites.
Tan Kaixin, General Manager at SEEDS Capital, remarked, “BluMaiden’s unique blend of microbiome expertise, analytics capabilities, and extensive clinical datasets positions them well to help life science clients generate novel insights. SEEDS Capital is excited to partner with BluMaiden as they develop their technologies and scale within Singapore’s emerging Precision Medicine hub”.
Aditya Mathur, Managing Director at Elev8.VC stated, “The future of drug discovery lies in harnessing vast clinical datasets. BluMaiden’s AI-guided approach unlocks unique data troves to accelerate the identification of promising small molecule drug candidates. We are impressed by their ability to translate complex data into actionable insights, leading to better patient outcomes”.
Michael Tilman, Chairman of BluMaiden, added: “We have an ambitious US-focused commercial plan and have developed initial strategic partnerships with major cloud-based tech firms and a growing network of healthcare and life science companies. After this successful seed round financing, we look forward to working with Elev8.vc and SEEDS Capital as we launch our commercialization strategy with a view to a significant Series-A raise next year”.
BluMaiden Biosciences, a Singapore-based biotech firm with a global presence, is a data-driven innovator that delivers actionable clinical insights to improve clinical trial decision-making through its Pharma Service. The company also identifies licensable small-molecule drugs using its flagship platform, MAIDEN. This platform combines computational biology with AI-guided analytics to enhance drug discovery.